Navigation Links
St. Jude finds signaling system that halts the growth of a childhood brain cancer
Date:3/14/2008

A discovery by St. Jude Childrens Research Hospital scientists suggests a safer way to treat medulloblastoma, a rare but often fatal childhood brain tumor. The group found that one of the brains signaling pathways inhibits the growth of the highly aggressive cancer cells.

The researchers discovered that three proteins, designated BMP2, BMP4 and BMP7, halted the growth of medulloblastoma tumors and induced the malignant cells to develop into normal neurons.

We think we have identified a pathway that can be used to prevent tumor formation and a potential target for therapy, said Martine F. Roussel, Ph.D., a member of the St. Jude Department of Genetics and Tumor Cell Biology. A report on this work appears in the March 15 issue of Genes & Development. Roussel is the papers senior author.

Medulloblastoma occurs in the cerebellum, which is located in the lower, rear part of the brain. This cancer strikes about 350 young children in the United States annually. Although treated patients have an overall five-year survival rate of 70 percent, conventional therapies combining surgery, irradiation and chemotherapy frequently lead to permanent neurocognitive impairment.

Several research teams are seeking to decipher the intricate signaling mechanisms that govern the proliferation of cells called granule neuron progenitors (GNPs). These cells go on to develop into neurons in the cerebellum during the first year of life. But the disruption of this differentiation process can trigger medulloblastoma.

We were interested in whether there were signals that inhibited tumor formation, Roussel said. And if there were, which ones were they? Could they be used to identify new therapeutic targets?

Previous research had shown that spurring GNPs to differentiate into neurons requires that BMPs bind to a set of receptors on the cell surface. This binding results in blocking the activity of a signaling pathway triggered by another
'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-495-3061
St. Jude Children's Research Hospital
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Survey Finds Many Americans Clueless About Eye Disease
2. Rodent study finds artificial butter chemical harmful to lungs
3. Damaged veins heal faster with heparin treatment, laboratory study finds
4. Study Finds Naturopathic Care for Chronic Low-Back Pain to be Efficacious, Cost-Effective
5. Large Disparities in Kidney Testing Based on Disease, Gender and State, Quest Diagnostics Health Trends(TM) Report Finds
6. Early bird doesnt always get worm, UNC researcher finds
7. Gender bias may affect care of people with osteoarthritis, study finds
8. Drosophila drug screen for fragile X syndrome finds promising compounds and potential drug targets
9. New Harris Survey Finds That Most Baby Boomers Underestimate Disability Risk
10. FDA Finds Contaminant in Baxters Recalled Heparin Products
11. Aromatherapy Falls Short, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays 2Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays 3Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays 4$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 2$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 3$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 4$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 5$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 6Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 2Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 4National Alliance for Hispanic Health Applauds Confirmation of Sonia Sotomayor as the Nations 111th Supreme Court Justice 53920 1The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 1The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 2The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 3The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 4The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 5The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 6The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 7The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 8The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 9The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 10The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 11The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 12The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 13Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 1Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 2Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 3Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 4Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 5Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 6Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 7Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 8Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 9Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 10Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 11Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 12Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 13Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 14Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 15Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 16Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 17Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 18Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 19Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 20Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 21Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 22